Pran device
Pran

Your health, reimagined.
Pran simplifies wellness through an innovative device and smart cartridge system—bringing convenience and care into your daily routine, painlessly.

Cartridge

Cartridge

The cartridge holds the liquid formulation (e.g., NAD+ or other treatments). It's designed for easy replacement, leak prevention, and optimal flow to the electrospray nozzle, ensuring smooth and efficient atomization delivery.

Cartridge

Cartridge explode diagram

The exploded diagram highlights three essential components: the mouthpiece for aerosol intake, the cartridge reservoir for holding the therapeutic liquid, and the electrospray system that creates fine droplets through ionization for optimal delivery.

Cartridge explode diagram

Device

Device explode diagram

This exploded diagram shows the internal components of Pran, a device designed to efficiently deliver therapeutic compounds like NAD+ using advanced electrospray technology for precise atomization.

Device explode diagram

ESP32 – Smart Controller

Acts as the brain of the device, managing voltage, spray patterns, and safety. Enables Bluetooth/Wi-Fi for app connectivity and electrospray parameter updates.

ESP32 Smart Controller

Electrospray Nozzle – Atomization System

Uses high voltage to create fine droplets through electrospray ionization, ensuring optimal particle size for effective compound delivery without thermal degradation.

Electrospray Nozzle Atomization System

Battery – Power Supply

High-voltage capable battery powers the electrospray system, designed for consistent performance and supports fast charging for reliable operation.

Battery Power Supply

Implementation Plan

2025

R&D & Patent Phase

Discover engineering process, file PCT patent, define target markets, and file national patents.

2025-2026

ISO & Regulatory

Research at ISO 17025 lab, pass ISO 10993 tests, and setup ISO 13485 factory for manufacturing standards.

2026-2027

Preclinical Studies

Conduct preclinical trials to establish safety and efficacy data before human testing.

2027-2029

Phase I Clinical Trial

First human testing phase to evaluate safety, dosage, and side effects in small groups.